Neoadjuvant chemoradiation for non ‐metastatic pancreatic cancer increases margin‐negative and node‐negative rates at resection
CONCLUSIONSNeoadjuvant chemoradiation remains a promising approach for non‐metastatic pancreatic cancer for improving resectability and pathological and clinical findings. Computed tomography may not fully demonstrate the effectiveness of neoadjuvant treatment.
Source: Journal of Digestive Diseases - Category: Gastroenterology Authors: Camille A. Berriochoa, May Abdel ‐Wahab, Charles M. Leyrer, Alok Khorana, R. Matthew Walsh, Aryavarta M. S. Kumar Tags: Original Article Source Type: research
More News: Cancer | Cancer & Oncology | CT Scan | Gastroenterology | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer | Pathology